Aduro BioTech Inc (NASDAQ:ADRO) traded up 12.1% during trading on Thursday . The company traded as high as $2.89 and last traded at $2.88. 1,011,701 shares traded hands during trading, an increase of 93% from the average session volume of 522,997 shares. The stock had previously closed at $2.57.
A number of equities research analysts have recently commented on the company. BidaskClub upgraded Aduro BioTech from a “sell” rating to a “hold” rating in a research report on Saturday, September 29th. HC Wainwright set a $8.00 price objective on Aduro BioTech and gave the company a “buy” rating in a research report on Tuesday, October 2nd. ValuEngine upgraded Aduro BioTech from a “strong sell” rating to a “sell” rating in a research report on Thursday, August 30th. William Blair reiterated a “buy” rating on shares of Aduro BioTech in a research report on Wednesday, October 3rd. Finally, Oppenheimer set a $10.00 price objective on Aduro BioTech and gave the company a “buy” rating in a research report on Tuesday, October 30th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the stock. Aduro BioTech currently has a consensus rating of “Hold” and a consensus target price of $8.63.
The firm has a market cap of $204.07 million, a PE ratio of -2.03 and a beta of 2.57.
In other news, insider Blaine Templeman sold 10,262 shares of the stock in a transaction on Monday, September 24th. The stock was sold at an average price of $5.81, for a total value of $59,622.22. Following the completion of the sale, the insider now owns 131,119 shares in the company, valued at $761,801.39. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stephen T. Isaacs sold 24,143 shares of the stock in a transaction on Thursday, September 13th. The shares were sold at an average price of $6.50, for a total value of $156,929.50. Following the completion of the sale, the insider now owns 356,996 shares of the company’s stock, valued at approximately $2,320,474. The disclosure for this sale can be found here. Insiders sold 46,927 shares of company stock valued at $294,918 in the last 90 days. Corporate insiders own 5.00% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ADRO. MetLife Investment Advisors LLC raised its holdings in shares of Aduro BioTech by 70.6% during the second quarter. MetLife Investment Advisors LLC now owns 31,799 shares of the biotechnology company’s stock worth $223,000 after acquiring an additional 13,156 shares in the last quarter. Alps Advisors Inc. raised its holdings in shares of Aduro BioTech by 14.2% during the second quarter. Alps Advisors Inc. now owns 114,257 shares of the biotechnology company’s stock worth $800,000 after acquiring an additional 14,187 shares in the last quarter. Swiss National Bank raised its holdings in shares of Aduro BioTech by 27.5% during the second quarter. Swiss National Bank now owns 73,300 shares of the biotechnology company’s stock worth $513,000 after acquiring an additional 15,800 shares in the last quarter. Credit Suisse AG raised its holdings in shares of Aduro BioTech by 54.5% during the third quarter. Credit Suisse AG now owns 47,915 shares of the biotechnology company’s stock worth $352,000 after acquiring an additional 16,896 shares in the last quarter. Finally, Capital Fund Management S.A. purchased a new stake in shares of Aduro BioTech during the second quarter worth $130,000. Institutional investors own 48.32% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This story was first posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.chaffeybreeze.com/2018/12/07/aduro-biotech-adro-trading-12-1-higher.html.
Aduro BioTech Company Profile (NASDAQ:ADRO)
Aduro BioTech, Inc, an immunotherapy company, focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases. The company is developing ADU-S100, which is in Phase I monotherapy study, as well as in Phase 1b combination study with an anti-PD1 immune checkpoint inhibitor; ADU-214 that is in Phase I clinical trials for the treatment of lung cancer; and ADU-741 for the treatment of prostate cancer.
Further Reading: How can you know how many shares are floating?
Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.